Webinar Series #3 Cardiovascular Disease and Type 2 Diabetes: Defining the Therapeutic Crossroads

  • October 24, 2020
  • 1:00 PM - 2:00 PM
  • Webinar

Registration


Registration is closed
Objectives:
  • Explore the relationships between T2D and CVD and CVD risk factors
  • Discuss definitions of primary and secondary prevention of CVD
  • Understand lipid and triglyceride management (statins, icosapent ethyl, oral antiplatelet therapy)
  • Primary and secondary prevention in type 2 diabetes including long-term oral anti-platelet trials in secondary prevention in T2D

BIO

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.

Copyright © 2016 Philippine Nurses Association of America. All rights reserved
Philippine Nurses Association of America is a 501(c)6 non-profit organization.
1346 How Lane, Suites 109, 110, North Brunswick, NJ 08902
infomypnaa@gmail.com

The Philippine Nurses Association of America, Inc (PNAA) receives monetary compensation for advertisements. The appearance of advertisements on the PNAA website and digital platforms is neither a guarantee nor an endorsement of the advertised products , services, or related advertiser claims by PNAA.

Powered by Wild Apricot Membership Software